New  Brunswick, N.J., and Leiden,  the Netherlands, 17 September 2010 -Johnson &
Johnson  (NYSE:  JNJ)  and  Crucell  N.V.  (NYSE  Euronext,  NASDAQ: CRXL; Swiss
Exchange:  CRX) today  announced that  they are  in advanced  negotiations for a
potential  public offer by Johnson & Johnson or an affiliate for all outstanding
ordinary  shares  of  Crucell  not  already  held  by  Johnson & Johnson and its
affiliates.   Johnson   &   Johnson,   through  an  affiliate,  currently  holds
approximately  17.9 percent  of  the  outstanding  shares  of  Crucell  and  has
submitted  a  statement  on  Schedule  13D to  the  U.S. Securities and Exchange
Commission  in connection with  its change in  investment intent with respect to
Crucell.

Under  the terms of the negotiations, which  are at an advanced stage, Johnson &
Johnson  or an affiliate would acquire all outstanding equity of Crucell that it
does  not  already  own  for  approximately  EUR1.75  billion,  which represents a
purchase  price  of  EUR24.75  per  share.  The  public offer would be an all cash
transaction.

This  potential  transaction  would  enable  Crucell  to  benefit from Johnson &
Johnson's  expertise and experience in  the development and commercialization of
pharmaceutical  products. The  companies expect  that Crucell's  strength in the
manufacture,  discovery and commercialization of  vaccines would create a strong
platform  for Johnson  & Johnson  in the  vaccine market.  After closing  of the
potential  transaction Johnson & Johnson  expects to maintain Crucell's existing
facilities,  to retain Crucell's  senior management and,  generally, to maintain
current employment levels. Johnson & Johnson also intends to keep Crucell as the
center  for vaccines within  the Johnson &  Johnson pharmaceutical group, and to
maintain Crucell's headquarters in Leiden.

Both companies expect that Crucell, as Johnson & Johnson's vaccine center, would
retain  its  entrepreneurial  culture  that  has fostered innovation and growth.
Johnson  & Johnson intends to continue to invest in the continued development of
Crucell's  products and pipeline  and support Crucell's  mission to increase the
number of people around the globe protected from infectious diseases.

In  accordance  with  customary  Dutch  practice,  and to adequately protect the
interest  of any minority shareholders, Johnson  & Johnson expects to retain two
independent  supervisory directors after  closing for such  time as is necessary
for Johnson & Johnson to acquire all of the outstanding equity of Crucell.

While  the parties  are still  in negotiations  with respect  to the  terms of a
definitive  agreement for  the potential  transaction, any  proposed transaction
would  be subject to customary pre-offer conditions, including consultation with
the relevant works council and trade unions, and customary offer conditions.

The Board of Directors of Johnson & Johnson and the Supervisory Board of Crucell
have authorized the companies to proceed with these negotiations for a potential
transaction.  Although  Johnson  &  Johnson's  due  diligence  is  substantially
complete,  the  transaction  remains  subject  to  negotiation  of  terms  of  a
definitive  agreement and  receipt of  internal approvals  of Johnson  & Johnson
management and the Management and Supervisory Boards of Crucell. There can be no
assurances that a definitive agreement will be entered into and that discussions
will  result  in  a  transaction.   In  addition,  the  terms  of  any potential
transaction may be different from what is described in this press release.


About Crucell
Crucell  N.V. (NYSE  Euronext, NASDAQ:  CRXL; Swiss  Exchange: CRX)  is a global
biopharmaceutical  company  focused  on  research  development,  production  and
marketing  of  vaccines,  proteins  and  antibodies  that  prevent  and/or treat
infectious  diseases. In  2009 alone, Crucell  distributed more than 115 million
vaccine  doses  in  more  than  100 countries  around  the  world, with the vast
majority  of doses (97%)  going to developing  countries. Crucell is  one of the
major  suppliers of vaccines to UNICEF and the developing world. Crucell was the
first   manufacturer  to  launch  a  fully-liquid  pentavalent  vaccine.  Called
Quinvaxem(®),   this   innovative  combination  vaccine  protects  against  five
important  childhood diseases. Over  130 million doses have  been sold since its
launch in 2006 in more than 50 GAVI countries. With this innovation, Crucell has
become  a major  partner in  protecting children  in developing countries. Other
products in Crucell's core portfolio include a vaccine against hepatitis B and a
virosome-adjuvanted  vaccine  against  influenza.  Crucell  also  markets travel
vaccines,  such as an oral anti-typhoid vaccine, an oral cholera vaccine and the
only  aluminum-free hepatitis A vaccine  on the market. The  Company has a broad
development  pipeline,  with  several  product  candidates  based  on its unique
PER.C6(®)  production technology. The Company  licenses its PER.C6(®) technology
and other technologies to the biopharmaceutical industry. Important partners and
licensees  include Johnson  & Johnson,  DSM Biologics, sanofi-aventis, Novartis,
Wyeth,  GSK,  CSL  and  Merck  &  Co.  Crucell  is  headquartered in Leiden, the
Netherlands,  with offices in  China, Indonesia, Italy,  Korea, Malaysia, Spain,
Sweden,  Switzerland, UK,  the USA  and Vietnam.  The Company employs over 1300
people. For more information, please visit www.crucell.com.

About Johnson & Johnson
Caring  for the world, one  person at a time..inspires  and unites the people of
Johnson & Johnson.  We embrace research and science - bringing innovative ideas,
products  and  services  to  advance  the  health  and well-being of people. Our
approximately  114,000 employees at  more than  250 Johnson &  Johnson companies
work  with partners in health  care to touch the  lives of over a billion people
every day throughout the world.

This  press  release  is  issued  pursuant  to  the provisions of article 5:25i
paragraph  2 of  the  Dutch  Financial  Supervision  Act  (Wet op het financieel
toezicht)  and article 4 paragraph 3 of the Dutch Decree on Public Takeover Bids
(Besluit openbare biedingen Wft).

This  document shall not constitute an offer  to sell or buy or the solicitation
of  an offer  to buy  or sell  any securities,  nor shall  there be  any sale or
purchase  of securities in any jurisdiction in which such offer, solicitation or
sale  would  be  unlawful  prior  to  registration  or  qualification  under the
securities laws of any such jurisdiction.

Forward-looking statements
(This  press  release  contains  "forward-looking  statements" as defined in the
Private  Securities  Litigation  Reform  Act  of 1995. All statements other than
statements   of   historical   fact   are   statements   that  could  be  deemed
forward-looking  statements. These statements are  based on current expectations
of future events. If underlying assumptions prove inaccurate or unknown risks or
uncertainties  materialize, actual results could  vary materially from Johnson &
Johnson's  and Crucell's  expectations and  projections. Risks and uncertainties
include  the ability  of the  parties to  reach a mutually acceptable definitive
agreement  and, if that occurs, whether  the conditions would then be satisfied;
general  industry conditions and competition; general domestic and international
economic   conditions,   such  as  interest  rate  and  currency  exchange  rate
fluctuations;  technological  advances  and  patents  attained  by  competitors;
challenges  inherent in new product  development, including obtaining regulatory
approvals;  domestic and foreign  health care reforms  and governmental laws and
regulations  affecting domestic and foreign operations; and trends toward health
care  cost containment. In addition, if and when the transaction is consummated,
there  will be risks and uncertainties related to Johnson & Johnson's ability to
successfully  integrate  the  products  and  employees  of Johnson & Johnson and
Crucell  as well as the ability to ensure continued performance or market growth
of   Crucell's  products.  A  further  list  and  description  of  these  risks,
uncertainties  and  other  factors  and  the  general  risks associated with the
respective  businesses of Johnson & Johnson and  Crucell can be found in Exhibit
99 of  Johnson & Johnson's Annual Report on  Form 10-K for the fiscal year ended
January  3, 2010, and  Crucell's  Annual  Report/  Form 20-F for the fiscal year
ended  December  31, 2009, as  filed  with  the  U.S.  Securities  and  Exchange
Commission  on  April  7, 2010, as  well  as  other  subsequent filings. Crucell
prepares  its  financial  statements  under  International  Financial  Reporting
Standards  (IFRS). Copies of  these filings are  available online atwww.sec.gov,
www.jnj.com,  www.crucell.com, or on request from  Johnson & Johnson or Crucell.
Neither  Johnson & Johnson nor Crucell  undertakes to update any forward-looking
statements as a result of new information or future events or developments.)

For further information please contact:

 Crucell N.V. - Media & Investors
 Oya Yavuz
 Vice President Corporate Communications & Investor Relations
 Tel. +31 (0)71 519 7064
 ir@crucell.com
 www.crucell.com


 Johnson & Johnson - Media

 Karen Manson             Bill Price

 Mob. + 32 479 89 47 99   Tel. +1 (732) 524 6623

                          Mob. +1 (732) 668 3735



 Johnson & Johnson - Investors

 Louise Mehrotra          Stan Panasewicz

 Tel. +1 (732) 524 6491   Tel. +1 (732) 524 2524
                          

[HUG#1444985]





PDF file: 
http://hugin.info/132631/R/1444985/388479.pdf




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Crucell N.V.  via Thomson Reuters ONE